Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF) : rationale, objectives, and design
BACKGROUND: Warfarin is widely prescribed for patients with heart failure without level 1 evidence, and an adequately powered randomized study is needed.
METHODS AND RESULTS: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction study is a National Institutes of Health-funded, randomized, double-blind clinical trial with a target enrollment of 2860 patients. It is designed to test with 90% power the 2-sided primary null hypothesis of no difference between warfarin (International Normalized Ratio 2.5-3) and aspirin (325 mg) in 3- to 5-year event-free survival for the composite endpoint of death, or stroke (ischemic or hemorrhagic) among patients with cardiac ejection fraction < or =35% who do not have atrial fibrillation or mechanical prosthetic heart valves. Secondary analyses will compare warfarin and aspirin for reduction of all-cause mortality, ischemic stroke, and myocardial infarction (MI), balanced against the risk of intracerebral hemorrhage, among women and African Americans; and compare warfarin and aspirin for prevention of stroke alone. Randomization is stratified by site, New York Heart Association (NYHA) heart class (I vs II-IV), and stroke or transient ischemic attack (TIA) within 1 year before randomization versus no stroke or TIA in that period. NYHA class I patients will not exceed 20%, and the study has a target of 20% (or more) patients with stroke or TIA within 12 months. Randomized patients receive active warfarin plus placebo or active aspirin plus placebo, double-blind.
CONCLUSION: The results should help guide the selection of optimum antithrombotic therapy for patients with left ventricular dysfunction.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2006 |
---|---|
Erschienen: |
2006 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Journal of cardiac failure - 12(2006), 1 vom: 30. Feb., Seite 39-46 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pullicino, Patrick [VerfasserIn] |
---|
Themen: |
5Q7ZVV76EI |
---|
Anmerkungen: |
Date Completed 03.10.2006 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM160928141 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM160928141 | ||
003 | DE-627 | ||
005 | 20231223091119.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231223s2006 xx |||||o 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0537.xml |
035 | |a (DE-627)NLM160928141 | ||
035 | |a (NLM)16500579 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pullicino, Patrick |e verfasserin |4 aut | |
245 | 1 | 0 | |a Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF) |b rationale, objectives, and design |
264 | 1 | |c 2006 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.10.2006 | ||
500 | |a Date Revised 21.11.2013 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Warfarin is widely prescribed for patients with heart failure without level 1 evidence, and an adequately powered randomized study is needed | ||
520 | |a METHODS AND RESULTS: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction study is a National Institutes of Health-funded, randomized, double-blind clinical trial with a target enrollment of 2860 patients. It is designed to test with 90% power the 2-sided primary null hypothesis of no difference between warfarin (International Normalized Ratio 2.5-3) and aspirin (325 mg) in 3- to 5-year event-free survival for the composite endpoint of death, or stroke (ischemic or hemorrhagic) among patients with cardiac ejection fraction < or =35% who do not have atrial fibrillation or mechanical prosthetic heart valves. Secondary analyses will compare warfarin and aspirin for reduction of all-cause mortality, ischemic stroke, and myocardial infarction (MI), balanced against the risk of intracerebral hemorrhage, among women and African Americans; and compare warfarin and aspirin for prevention of stroke alone. Randomization is stratified by site, New York Heart Association (NYHA) heart class (I vs II-IV), and stroke or transient ischemic attack (TIA) within 1 year before randomization versus no stroke or TIA in that period. NYHA class I patients will not exceed 20%, and the study has a target of 20% (or more) patients with stroke or TIA within 12 months. Randomized patients receive active warfarin plus placebo or active aspirin plus placebo, double-blind | ||
520 | |a CONCLUSION: The results should help guide the selection of optimum antithrombotic therapy for patients with left ventricular dysfunction | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 7 | |a Anticoagulants |2 NLM | |
650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
650 | 7 | |a Warfarin |2 NLM | |
650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
650 | 7 | |a Aspirin |2 NLM | |
650 | 7 | |a R16CO5Y76E |2 NLM | |
700 | 1 | |a Thompson, John L P |e verfasserin |4 aut | |
700 | 1 | |a Barton, Bruce |e verfasserin |4 aut | |
700 | 1 | |a Levin, Bruce |e verfasserin |4 aut | |
700 | 1 | |a Graham, Susan |e verfasserin |4 aut | |
700 | 1 | |a Freudenberger, Ronald S |e verfasserin |4 aut | |
700 | 0 | |a WARCEF Investigators |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of cardiac failure |d 1995 |g 12(2006), 1 vom: 30. Feb., Seite 39-46 |w (DE-627)NLM087692775 |x 1532-8414 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2006 |g number:1 |g day:30 |g month:02 |g pages:39-46 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2006 |e 1 |b 30 |c 02 |h 39-46 |